Floatz logo

FILGRASTIM

Locally Advanced Urothelial Carcinoma

Mayo Clinicprotein_peptidePhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
33/ 100
Competitive Position
95/ 100

Competitive context

10 Active assets in the Locally Advanced Urothelial Carcinoma cohort.

Asset / SponsorPhaseRating
Durvalumab
Alliance for Clinical Trials in Oncology
Phase 3BB
Relatlimab
Exelixis
Phase 2B
PAN-FGFR TYROSINE KINASE INHIBITOR JNJ-42756493
National Cancer Institute (NCI)
Phase 2B
PROPRANOLOL
Emory University
Phase 2CCC
Polyiclc
Mayo Clinic
Phase 1/2CCC

View all 10 →

Same molecule, other indications

FILGRASTIM is also rated in:

plasma cell myelomaDormant
BBB
Indicative ·
79 / 100
View asset →
Burkitt lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
Hodgkins lymphomaDormant
BBB
Indicative ·
76 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →